Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–17 of 17 results
Advanced filters: Author: Basharut A. Syed Clear advanced filters

  • Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease, is predicted to become the leading reason for liver transplantation by 2020. This analysis provides an overview of emerging therapies for NASH.

    • Sorcha Cassidy
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 15, P: 745-746

  • Dry age-related macular degeneration (AMD) is a major cause of vision loss in the elderly. Evans and Syed discuss the pipeline of therapies for dry AMD and the future of the market.

    • James B. Evans
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 12, P: 501-502

  • This article analyses the market for rheumatoid arthritis therapies, which is growing rapidly, with a range of new disease-modifying drugs poised to enter in the next few years.

    • Kritika Chaudhari
    • Salman Rizvi
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 15, P: 305-306

  • There are an estimated 1.3 billion smokers worldwide, and nearly six million people die from tobacco-related diseases each year. This article discusses smoking cessation drugs that are in development or on the market, and provides an outlook for their commercial potential.

    • Basharut A. Syed
    • Kritika Chaudhari
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 12, P: 97-98

  • This article analyses the evolution of the market for genomic sequencing technologies in the light of major reductions in sequencing costs and time, and the growth in potential pharmacogenomics applications.

    • Sharmarke Mohamed
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 12, P: 341-342

  • The standard of care for the treatment of acute myeloid leukaemia (AML) has changed little for decades, but there are now a number of interesting agents in development. This analysis overviews the late-stage AML pipeline and the changing AML market.

    • Sorcha Cassidy
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 15, P: 527-528

  • This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially.

    • Salman Rizvi
    • Kritika Chaudhari
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 14, P: 745-746

  • Products based on stem cells show promise in diverse therapeutic areas, including cardiovascular and autoimmune diseases. This article analyses the late-stage pipeline of stem cell therapies and provides a market overview.

    • Basharut A. Syed
    • James B. Evans
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 12, P: 185-186

  • This analysis provides an overview of novel antihypertensive products, many of which are fixed-dose combinations of different drug classes, and provides an outlook on their likely impact on the market.

    • M. Adam Ali
    • Salman Rizvi
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 16, P: 309-310

  • The market for drugs to treat wet age-related macular degeneration (AMD) is expected to more than double by 2016. This article investigates unmet needs and discusses current agents in the pipeline.

    • Basharut A. Syed
    • James B. Evans
    • Leonard Bielory
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 11, P: 827

  • The market for colorectal cancer therapies, which is currently dominated by drugs targeting vascular endothelial growth factor and epidermal growth factor receptor, is poised for change with the anticipated entry of immunotherapies and other targeted drugs.

    • Sorcha Cassidy
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 16, P: 525-526

  • Current treatments for cystic fibrosis are largely symptomatic, but the first disease-modifying drug has recently been approved and others are progressing. This article examines the multitude of agents in the clinical pipeline and their potential market impact in the next 5 years.

    • Basharut A. Syed
    • Bashar Hamad
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 13, P: 721-722

  • Thrombotic events are a major complication of cardiovascular disease. Despite the availability of a large range of antithrombotic therapies, demand persists for safe, effective new drugs and antidotes that allow control of their activity. This article investigates the antithrombotic drug pipeline and the changing landscape of the antithrombotics market.

    • Kritika Chaudhari
    • Bashar Hamad
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 13, P: 571-572

  • Several new drugs have recently been approved for the treatment of breast cancer, and this analysis provides a market outlook as well as an insight into the pipeline of agents in late-stage development.

    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 14, P: 233-234

  • Next-generation antibody (NGA) therapeutics incorporate architectural changes that allow for increased efficacy and product differentiation. This analysis provides an overview of the different types of NGAs in development and an outlook of their market potential.

    • James B. Evans
    • Basharut A. Syed
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 13, P: 413-414